Form 4: Cidara Therapeutics Director Daniel Burgess Granted 11,100 Stock Options

Cidara Therapeutics, Inc. Director Daniel D. Burgess has been granted 11,100 stock options with an exercise price of $21.31, as disclosed in a recent SEC Form 4 filing.

Summary

• Daniel D. Burgess, a Director of Cidara Therapeutics, Inc. (CDTX), acquired 11,100 stock options.
• The transaction date for the option grant was June 18, 2025.
• The exercise price for these stock options is $21.31 per share.
• The options are set to vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Burgess beneficially owns 11,100 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a routine filing, the grant of options to a director signifies continued commitment and alignment of interests, which is generally viewed favorably by investors.

Positives

• The acquisition of stock options by a director indicates continued alignment of management's interests with those of shareholders, as the options' value is tied to the company's stock performance.
• The grant of options is a common form of executive compensation, incentivizing long-term commitment and performance.

Future Outlook

The vesting schedule for the stock options, set for June 18, 2026, or the day prior to the 2026 annual meeting, indicates a future commitment period for the director, aligning their incentives with the company's long-term performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all industries, including biotechnology. It reflects standard compensation practices for directors, aiming to align their financial interests with the company's success.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Management/Employees: This transaction is part of the compensation structure for a director, reflecting standard practices for incentivizing leadership.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the day prior to Cidara Therapeutics' 2026 annual meeting of stockholders.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Stock Options, Insider Trading, Form 4, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals